NCT05554354 2026-03-03Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Terminated1 enrolled